Can You Take Mounjaro If You've Had Your Gallbladder Removed?

How gallbladder removal changes the picture for GLP-1 treatment

The gallbladder's job is to store bile and release it in controlled bursts when fatty food arrives in the small intestine. After a cholecystectomy, bile drips continuously from the liver into the gut instead. For most people this settles into a workable pattern, but it can make the digestive system more reactive, particularly to anything that further slows digestion.

Mounjaro (tirzepatide) slows gastric emptying, that's part of how it reduces appetite and improves blood-sugar regulation. For someone without a gallbladder, slower gastric emptying means bile acids and fat interact differently from the start of digestion. That isn't an automatic barrier to treatment, but it is a real physiological consideration. Our Mounjaro overview explains how the medicine works in the broader sense, including its dual GIP and GLP-1 receptor mechanism.

A question our prescribers hear most weeks is some version of this: "I had my gallbladder out years ago and everything's been fine, does that change what I can take?" If that question applies to you, our dedicated page on taking Mounjaro after gallbladder removal covers the honest answer in full, including why a past cholecystectomy needs to be part of the conversation, not because it rules treatment out, but because it shapes how a prescriber thinks about your GI baseline going in.

What the evidence says about gallbladder side effects on tirzepatide

Clinical trials of tirzepatide in people who had their gallbladder intact showed gallbladder-related events (including gallstones and cholecystitis) as a recognised side effect of the medicine. The NHS patient information for tirzepatide lists gallbladder problems among the effects patients should be aware of, and the full picture is detailed in the NHS tirzepatide medicines page.

For someone who has already had their gallbladder removed, this particular risk pathway is no longer present. In that sense, one category of concern is off the table. The tradeoff is that post-cholecystectomy digestive patterns vary considerably from person to person. Some people have no ongoing symptoms at all; others deal with looser stools or urgency because bile isn't being stored. Tirzepatide's GI side-effect profile (which includes nausea, diarrhoea and constipation) could interact with whichever pattern is already established.

There isn't a large dedicated trial of tirzepatide specifically in post-cholecystectomy patients, so prescribers work from the broader evidence base, their clinical knowledge of how the drug behaves, and a detailed account of your individual GI history. You can explore the full side-effect profile of Mounjaro for more context on what's commonly reported.

The GI side effects most worth flagging if you have no gallbladder

Nausea is the most frequently reported side effect of tirzepatide, particularly in the first few weeks and after dose increases. It usually settles. Diarrhoea is also common, and this is the side effect most worth monitoring carefully for someone whose digestive system already runs on the faster side after cholecystectomy. Constipation, by contrast, may actually offer some relief for people who've had loose-stool symptoms since their operation, though that's never a reason to start treatment, and it wouldn't be predictable.

The GI side effects linked to Mounjaro are documented on the electronic Medicines Compendium, where the full Summary of Product Characteristics sets out frequencies and clinical context. That's the reference a prescriber uses when weighing your individual history against the drug's known profile.

For context on a specific side effect that sometimes surprises people, this page on thrush and Mounjaro is worth a look, it illustrates how the medicine can affect the body in ways not immediately obvious from the headline GI list.

When to seek medical help, and what to watch for

On tirzepatide, certain symptoms always warrant prompt medical attention. Severe, persistent abdominal pain (especially if it radiates towards the back) should be assessed urgently; the MHRA highlighted acute pancreatitis as a known but serious infrequent risk in its January 2026 Drug Safety Update for GLP-1 medicines. That guidance applies regardless of whether or not you have a gallbladder.

Signs of significant dehydration from prolonged vomiting or diarrhoea, any allergic reaction (rash, swelling, difficulty breathing), and sudden changes in vision should all prompt you to contact NHS 111 or your GP without delay. If you have any doubt about a new symptom, don't wait for your next scheduled check-in.

Suspected side effects can be reported directly to the MHRA through the Yellow Card scheme. This matters, it's how post-market safety signals get identified, and reports from real patients are genuinely valuable.

Our prescribers talk through suitability and likely side effects as a standard part of every consultation, not as a formality. You can start a free consultation to have your own situation reviewed properly. For related reading, the pages on taking Mounjaro after gallbladder removal and on what it means to have no gallbladder cover adjacent questions in more detail.